- Home
- INV vs MLYS Comparison
INV vs MLYS Comparison
Compare INV & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INV
- MLYS
- Stock Information
- Founded
- INV 2015
- MLYS 2019
- Country
- INV United States
- MLYS United States
- Employees
- INV N/A
- MLYS N/A
- Industry
- INV
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- INV
- MLYS Health Care
- Exchange
- INV NYSE
- MLYS Nasdaq
- Market Cap
- INV 615.9M
- MLYS 510.6M
- IPO Year
- INV N/A
- MLYS 2023
- Fundamental
- Price
- INV $7.79
- MLYS $10.52
- Analyst Decision
- INV Strong Buy
- MLYS Strong Buy
- Analyst Count
- INV 1
- MLYS 3
- Target Price
- INV $16.00
- MLYS $27.00
- AVG Volume (30 Days)
- INV 47.4K
- MLYS 384.1K
- Earning Date
- INV 03-18-2025
- MLYS 02-12-2025
- Dividend Yield
- INV N/A
- MLYS N/A
- EPS Growth
- INV N/A
- MLYS N/A
- EPS
- INV N/A
- MLYS N/A
- Revenue
- INV $988,000.00
- MLYS N/A
- Revenue This Year
- INV $2,784.42
- MLYS N/A
- Revenue Next Year
- INV $215.34
- MLYS N/A
- P/E Ratio
- INV N/A
- MLYS N/A
- Revenue Growth
- INV 4.88
- MLYS N/A
- 52 Week Low
- INV $7.75
- MLYS $8.24
- 52 Week High
- INV $18.75
- MLYS $15.25
- Technical
- Relative Strength Index (RSI)
- INV N/A
- MLYS 55.60
- Support Level
- INV N/A
- MLYS $9.69
- Resistance Level
- INV N/A
- MLYS $10.82
- Average True Range (ATR)
- INV 0.00
- MLYS 0.80
- MACD
- INV 0.00
- MLYS 0.17
- Stochastic Oscillator
- INV 0.00
- MLYS 88.37
About INV INNVENTURE INC
Innventure Inc creates, funds, operates, and rapidly scales companies in strategic collaboration with MNCs. It provides company creation, corporate strategy, technology optimization, operations, commercialization, and funding. Innventure analyzes the market, including proprietary data provided by MNCs, to identify where their well-protected, breakthrough technologies address market needs and have the potential to create $1B+ in new enterprise value.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.